1. Overcoming disease-specific matrix effect in a clinical pharmacokinetic assay using a microfluidic immunoassay technology. (August 2017) Authors: Williams, Kathi; Erickson, Rich; Fischer, Saloumeh Kadkhodayan Journal: Bioanalysis Issue: Volume 9:Number 16(2017) Page Start: 1207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Utilizing design of experiments to characterize assay robustness. (September 2012) Authors: Cowan, Kyra J; Erickson, Rich; Sue, Brian; Delarosa, Reginald; Gunter, Bert; Coleman, Daniel A; Gilbert, Houston; Song, An; Fischer, Saloumeh Kadkhodayan Journal: Bioanalysis Issue: Volume 4:Number 17(2012) Page Start: 2127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Utilizing design of experiments to characterize assay robustness. (September 2012) Authors: Cowan, Kyra J; Erickson, Rich; Sue, Brian; Delarosa, Reginald; Gunter, Bert; Coleman, Daniel A; Gilbert, Houston; Song, An; Fischer, Saloumeh Kadkhodayan Journal: Bioanalysis Issue: Volume 4:Number 17(2012) Page Start: 2127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P035 ETROLIZUMAB TREATMENT MODULATES SOLUBLE MADCAM-1 LEVELS IN SERUM IN PATIENTS WITH CROHN'S DISEASE. (7th February 2019) Authors: Sandborn, William J; Panes, Julian; Fuh, Franklin; Erickson, Rich; Jacob, Rhian; Zhang, Wenhui; Tang, Meina T; McBride, Jacqueline Journal: Inflammatory bowel diseases Issue: Volume 25(2019)Supplement 1 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL‐22Fc): A Potential Therapy for Epithelial Injury. Issue 1 (12th August 2018) Authors: Rothenberg, Michael E.; Wang, Yehong; Lekkerkerker, Annemarie; Danilenko, Dimitry M.; Maciuca, Romeo; Erickson, Rich; Herman, Ann; Stefanich, Eric; Lu, Timothy T. Journal: Clinical pharmacology & therapeutics Issue: Volume 105:Issue 1(2019) Page Start: 177 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis. (26th November 2017) Authors: Wei, Xiaohui; Gibiansky, Leonid; Wang, Yehong; Fuh, Franklin; Erickson, Rich; O'Byrne, Sharon; Tang, Meina T. Journal: Journal of clinical pharmacology Issue: Volume 58:Number 3(2018) Page Start: 386 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Etrolizumab Treatment Does Not Modify Levels of VCAM‐1 in Ulcerative Colitis Patients: 1880. (October 2015) Authors: Fuh, Franklin; Looney, Caroline; Tew, Wei; Erickson, Rich; Maciuca, Romeo; Tang, Meina; Keir, Mary; Vermeire, Séverine; O'Byrne, Sharon; Ramirez‐Montagut, Teresa Journal: American journal of gastroenterology Issue: Volume 110(2015)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Etrolizumab Treatment Modulates MAdCAM‐1 Levels in Serum in Ulcerative Colitis Patients: 1876. (October 2015) Authors: Fuh, Franklin; Erickson, Rich; Schofield, Cheryl; Tang, Meina; Maciuca, Romeo; Keir, Mary; Vermeire, Séverine; O'Byrne, Sharon; Ramirez‐Montagut, Teresa Journal: American journal of gastroenterology Issue: Volume 110(2015)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗